 |
9 Diseases |  |
1 Trial |
|
1 Trial |  |
139 News |  |
| «12 |
- |||||| otilimab (GSK3196165) / GSK
Enrollment open, Combination therapy: contRAst 3: Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors (clinicaltrials.gov) - Nov 17, 2019
P3, N=525, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting
- | otilimab (GSK3196165) / GSK
New P3 trial, Combination therapy: contRAst 3: Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors (clinicaltrials.gov) - Oct 21, 2019
P3, N=525, Not yet recruiting, Sponsor: GlaxoSmithKline
- otilimab (GSK3196165) / GSK
Exploratory Analysis of a Phase 2b Study Confirms Substantial Pain Improvement with Anti-GM-CSF Monoclonal Antibody Otilimab (GSK3196165) in Patients (Pts) with Active RA (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1473;
P2b
Phase 3 studies are ongoing in pts with moderate to severe active RA and will further assess the overall clinical benefit and sustained improvement in pain symptoms with weekly dosing of otilimab plus MTX. Study funded by GSK (NCT02504671); GSK involved in design and data analysis.
- ||| otilimab (GSK3196165) / GSK
GSK to Initiate P-III ContRAst Studies of Otilimab to Treat Moderate to Severe Rheumatoid Arthritis @GSK https://t.co/d3vq3j9YXM (Twitter) - Jul 3, 2019
- |||||| otilimab (GSK3196165) / GSK
Enrollment open, Combination therapy: contRAst 2: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) (clinicaltrials.gov) - Jun 16, 2019
P3, N=1500, Recruiting, Sponsor: GlaxoSmithKline
Study funded by GSK (NCT02504671); GSK involved in design and data analysis. Not yet recruiting --> Recruiting
- |||||||||| otilimab (GSK3196165) / GSK
New P3 trial, Combination therapy: contRAst 1: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (clinicaltrials.gov) - Jun 11, 2019
P3, N=1500, Recruiting, Sponsor: GlaxoSmithKline
- |||||||||| otilimab (GSK3196165) / GSK
New P3 trial, Combination therapy: contRAst 2: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) (clinicaltrials.gov) - Jun 2, 2019
P3, N=1500, Not yet recruiting, Sponsor: GlaxoSmithKline
- |||| otilimab (GSK3196165) / GSK
Trial completion, Combination therapy: Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis (clinicaltrials.gov) - Jan 18, 2018
P2b, N=222, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | otilimab (GSK3196165) / GSK
Trial completion, Enrollment change, Combination therapy: Evaluation of Pharmacokinetics and Safety of GSK3196165 in Combination With Methotrexate in Japanese Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jan 11, 2018
P2, N=15, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=40 --> 15
- | otilimab (GSK3196165) / GSK
Trial completion, P2a data: A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis (clinicaltrials.gov) - Dec 13, 2017
P2a, N=44, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | N=40 --> 15 Active, not recruiting --> Completed
- | otilimab (GSK3196165) / GSK
Trial completion, Combination therapy: Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - Nov 27, 2017
P2a, N=39, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| otilimab (GSK3196165) / GSK
Enrollment closed, Trial primary completion date, Combination therapy: Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis (clinicaltrials.gov) - Sep 21, 2017
P2b, N=210, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Dec 2017 | Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Dec 2017
- | otilimab (GSK3196165) / GSK
Enrollment closed, Combination therapy: Evaluation of Pharmacokinetics and Safety of GSK3196165 in Combination With Methotrexate in Japanese Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 21, 2017
P2, N=40, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Dec 2017 | Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Dec 2017 Recruiting --> Active, not recruiting
- | otilimab (GSK3196165) / GSK
Enrollment closed, Trial primary completion date, Combination therapy: Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jul 17, 2017
P2a, N=40, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Oct 2017
- | otilimab (GSK3196165) / GSK
Enrollment closed, P2a data: A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis (clinicaltrials.gov) - Jun 22, 2017
P2a, N=40, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Oct 2017 Recruiting --> Active, not recruiting
- otilimab (GSK3196165) / GSK
Trial primary completion date, Combination therapy: Evaluation of Pharmacokinetics and Safety of GSK3196165 in Combination With Methotrexate in Japanese Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 21, 2017
P2, N=40, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2018 --> Dec 2017
- otilimab (GSK3196165) / GSK
Trial primary completion date, Combination therapy: Evaluation of Pharmacokinetics and Safety of GSK3196165 in Combination With Methotrexate in Japanese Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - May 31, 2017
P2, N=40, Recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Jul 2018 --> Dec 2017 Trial primary completion date: Dec 2017 --> Jul 2018
- otilimab (GSK3196165) / GSK
P2a data, Trial primary completion date: A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis (clinicaltrials.gov) - Apr 7, 2017
P2a, N=40, Recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Dec 2017 --> Jul 2018 Trial primary completion date: Aug 2017 --> Nov 2017
- | otilimab (GSK3196165) / GSK
Enrollment open, Combination therapy: Evaluation of Pharmacokinetics and Safety of GSK3196165 in Combination With Methotrexate in Japanese Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Feb 21, 2017
P2, N=40, Recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Aug 2017 --> Nov 2017 Not yet recruiting --> Recruiting
- | otilimab (GSK3196165) / GSK
New P2 trial, Combination therapy: Evaluation of Pharmacokinetics and Safety of GSK3196165 in Combination With Methotrexate in Japanese Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jan 23, 2017
P2, N=40, Not yet recruiting, Sponsor: GlaxoSmithKline
- | otilimab (GSK3196165) / GSK
Enrollment open, Combination therapy: Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jul 13, 2016
P2a, N=40, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | otilimab (GSK3196165) / GSK
New P2a trial, Combination therapy: Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jun 15, 2016
P2a, N=40, Not yet recruiting, Sponsor: GlaxoSmithKline
- | otilimab (GSK3196165) / GSK
Enrollment open, P2a data: A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis (clinicaltrials.gov) - Apr 18, 2016
P2a, N=40, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | otilimab (GSK3196165) / GSK
New P2a trial, P2a data: A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis (clinicaltrials.gov) - Feb 17, 2016
P2a, N=40, Not yet recruiting, Sponsor: GlaxoSmithKline
- |||| otilimab (GSK3196165) / GSK
Combination therapy: Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis (clinicaltrials.gov) - Sep 16, 2015
P2b, N=210, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| otilimab (GSK3196165) / GSK
New P2b trial, Combination therapy: Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis (clinicaltrials.gov) - Jul 22, 2015
P2b, N=210, Not yet recruiting, Sponsor: GlaxoSmithKline
- | otilimab (GSK3196165) / GSK
Trial completion: Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis (clinicaltrials.gov) - Feb 13, 2014
P1/2, N=30, Completed, Sponsor: MorphoSys AG
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||| otilimab (GSK3196165) / GSK
Trial completion: Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jul 15, 2012
P1/2, N=96, Completed, Sponsor: MorphoSys AG
Recruiting --> Completed Active, not recruiting --> Completed
- | otilimab (GSK3196165) / GSK
New P1/2 trial: Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis (clinicaltrials.gov) - Jan 23, 2012
P1/2, N=30, Completed, Sponsor: MorphoSys AG